INVEGA TRINZA 263mg/1.315mL ProlongedRelease Suspension for Intramuscular Injection

Manufacturer
JANSSEN PHARMACEUTICA N.V.(BELGIUM)

Registraction Number
MAL20046068AZ

Content:
INVEGA TRINZA (Paliperidone Palmitate) 263mg/1.315mL Prolonged-Release Suspension for Intramuscular Injection contains the active ingredient paliperidone palmitate. Each prefilled syringe contains 263 mg of paliperidone palmitate in 1.315 mL of suspension.
Indications:
INVEGA TRINZA is used for the treatment of:
Schizophrenia: In patients who have been adequately treated with INVEGA SUSTENNA (1-month paliperidone palmitate) for at least four months2.
Instructions:
Dosage: The medication should be administered once every 3 months2.
Administration:
-Preparation: Shake the syringe vigorously for at least 15 seconds to ensure a homogeneous suspension2.
-Injection: Administer the injection intramuscularly into the deltoid or gluteal muscle. The needle selection depends on the patient's weight and injection site:
-For deltoid injection: Use a 22G x 1" needle for patients weighing less than 90 kg, and a 22G x 1½" needle for patients weighing 90 kg or more2.
-For gluteal injection: Use a 22G x 1½" needle regardless of the patient's weight2.
-Procedure: Inject slowly, deep into the muscle, taking care to avoid injection into a blood vessel. Do not divide the dose into multiple injections2